Sign In
Buy MCRB
$4.83
+0.0500 (+1.05%)
At Close: Jul 31, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from its Phase 3 ECOSPOR III study evaluating SER-109, an in
Why Seres Therapeutics Stock Is Soaring Today
03:35pm, Wednesday, 15'th Sep 2021
The company completed its target enrollment in a pivotal clinical study.
Why Seres Therapeutics Shares Are Trading Higher Today
03:25pm, Wednesday, 15'th Sep 2021
Seres Therapeutics (NASDAQ:MCRB) shares are trading higher after the company achieved enrollment of 300 subjects in its Phase 3 ECOSPOR IV study of SER-109. Seres Therapeutics' stock has been rising
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has achieved enrollment of 300 subjects with the ECOSPOR IV op
Seres Therapeutics: Here We Go Again
03:17pm, Thursday, 09'th Sep 2021
The microbiome has arrived as a significant area of opportunity for new treatments of infectious and chronic conditions. While the importance of the microbiome is clear, validated products remain elus
Cathie Wood's ARK Invest Sells Over 840,000 Shares of Seres Therapeutics
08:35am, Tuesday, 31'st Aug 2021
One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood sold over 840,000 shares of Seres Therapeutics Inc.
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2021 Results - Earnings Call Transcript
12:37pm, Tuesday, 03'rd Aug 2021
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2021 Results - Earnings Call Transcript
Recap: Seres Therapeutics Q2 Earnings
07:34am, Tuesday, 03'rd Aug 2021
Shares of Seres Therapeutics (NASDAQ:MCRB) moved higher by 2.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 89.29% year over year to ($0.53),
Why Seres Therapeutics Stock Is Crashing Today
11:51am, Thursday, 22'nd Jul 2021
The company reported disappointing results from a phase 2b clinical study.
MCRB Stock Fell Over 50% Pre-Market: Why It Happened
09:12am, Thursday, 22'nd Jul 2021
The stock price of Seres Therapeutics Inc (NASDAQ: MCRB) fell by over 50% pre-market. This is why it happened.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcas
Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage Study
07:22am, Thursday, 22'nd Jul 2021
Seres Therapeutics Inc (NASDAQ: MCRB) has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). The study did no
Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options
09:46am, Wednesday, 07'th Jul 2021
Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021
12:26am, Tuesday, 06'th Jul 2021
Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021
Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases
11:01am, Thursday, 01'st Jul 2021
Seres Therapeutics Inc (NASDAQ: MCRB) has inked a $525-million deal with Nestlé Health Science to commercialize SER-109 if it can win FDA approval. SER-109 is an oral, live microbiome therapy under
